Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Troponin T | 11 | 2021 | 786 | 2.870 |
Why?
|
Cardiovascular Diseases | 55 | 2024 | 15657 | 2.630 |
Why?
|
Natriuretic Peptide, Brain | 10 | 2020 | 1750 | 2.250 |
Why?
|
Interleukin-1beta | 12 | 2020 | 1026 | 1.680 |
Why?
|
Diabetes Mellitus, Type 2 | 36 | 2024 | 12245 | 1.610 |
Why?
|
Anti-Inflammatory Agents | 8 | 2020 | 1805 | 1.510 |
Why?
|
Fluorobenzenes | 5 | 2015 | 179 | 1.330 |
Why?
|
C-Reactive Protein | 19 | 2022 | 3853 | 1.320 |
Why?
|
Peptide Fragments | 7 | 2020 | 5143 | 1.190 |
Why?
|
Atherosclerosis | 11 | 2024 | 3420 | 1.070 |
Why?
|
Troponin I | 4 | 2020 | 659 | 1.070 |
Why?
|
Heart Failure | 16 | 2024 | 11882 | 0.960 |
Why?
|
Cholesterol, LDL | 10 | 2024 | 2392 | 0.950 |
Why?
|
Lupus Erythematosus, Systemic | 10 | 2024 | 2160 | 0.910 |
Why?
|
Antibodies, Monoclonal | 11 | 2018 | 9244 | 0.850 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2022 | 3250 | 0.820 |
Why?
|
Myocardium | 4 | 2020 | 4765 | 0.780 |
Why?
|
Sulfonamides | 5 | 2015 | 1982 | 0.760 |
Why?
|
Glucosides | 4 | 2024 | 533 | 0.740 |
Why?
|
Hypoglycemic Agents | 15 | 2024 | 3108 | 0.730 |
Why?
|
Myocardial Ischemia | 3 | 2016 | 2132 | 0.730 |
Why?
|
Cholesterol, HDL | 7 | 2022 | 1812 | 0.710 |
Why?
|
Stroke | 19 | 2024 | 9741 | 0.670 |
Why?
|
Pyrimidines | 5 | 2015 | 3043 | 0.640 |
Why?
|
Benzhydryl Compounds | 4 | 2024 | 944 | 0.640 |
Why?
|
Colchicine | 1 | 2020 | 257 | 0.630 |
Why?
|
Myocardial Infarction | 18 | 2024 | 11513 | 0.620 |
Why?
|
Heart Injuries | 1 | 2020 | 207 | 0.610 |
Why?
|
Therapies, Investigational | 1 | 2019 | 110 | 0.600 |
Why?
|
Peripheral Arterial Disease | 3 | 2019 | 1304 | 0.590 |
Why?
|
Risk Factors | 48 | 2024 | 74881 | 0.590 |
Why?
|
Prediabetic State | 2 | 2021 | 547 | 0.570 |
Why?
|
Cardiovascular Abnormalities | 1 | 2018 | 148 | 0.560 |
Why?
|
Vasculitis | 1 | 2020 | 528 | 0.520 |
Why?
|
Medicaid | 7 | 2020 | 2836 | 0.500 |
Why?
|
Troponin | 2 | 2016 | 536 | 0.500 |
Why?
|
Risk Assessment | 17 | 2024 | 24295 | 0.490 |
Why?
|
Drug Approval | 3 | 2019 | 820 | 0.490 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2016 | 91 | 0.490 |
Why?
|
Double-Blind Method | 18 | 2023 | 12430 | 0.480 |
Why?
|
Thrombosis | 4 | 2021 | 2953 | 0.480 |
Why?
|
Vitamin E | 3 | 2015 | 872 | 0.480 |
Why?
|
Proprotein Convertases | 1 | 2015 | 95 | 0.480 |
Why?
|
Methotrexate | 3 | 2020 | 1719 | 0.470 |
Why?
|
Metformin | 3 | 2017 | 908 | 0.460 |
Why?
|
Diabetes Mellitus | 4 | 2024 | 5887 | 0.450 |
Why?
|
Inflammasomes | 1 | 2019 | 541 | 0.440 |
Why?
|
Women's Health | 3 | 2015 | 2081 | 0.440 |
Why?
|
Anticholesteremic Agents | 2 | 2024 | 970 | 0.440 |
Why?
|
Heparin | 5 | 2021 | 1636 | 0.440 |
Why?
|
Coronary Disease | 4 | 2015 | 5915 | 0.420 |
Why?
|
Hematuria | 1 | 2014 | 232 | 0.420 |
Why?
|
Atrial Fibrillation | 8 | 2022 | 5182 | 0.410 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 5 | 2024 | 317 | 0.410 |
Why?
|
Humans | 123 | 2024 | 766766 | 0.410 |
Why?
|
Middle Aged | 75 | 2024 | 223257 | 0.410 |
Why?
|
Lipids | 6 | 2019 | 3319 | 0.410 |
Why?
|
Incidence | 23 | 2020 | 21525 | 0.400 |
Why?
|
Death, Sudden, Cardiac | 1 | 2020 | 1567 | 0.390 |
Why?
|
Blood Glucose | 5 | 2019 | 6422 | 0.390 |
Why?
|
Death | 1 | 2016 | 685 | 0.380 |
Why?
|
Dyslipidemias | 1 | 2019 | 872 | 0.380 |
Why?
|
Patient Admission | 1 | 2019 | 1364 | 0.380 |
Why?
|
Aspirin | 4 | 2021 | 3135 | 0.370 |
Why?
|
Hydrochlorothiazide | 2 | 2008 | 95 | 0.370 |
Why?
|
Benzoxazoles | 2 | 2024 | 92 | 0.360 |
Why?
|
Motor Activity | 2 | 2011 | 2711 | 0.360 |
Why?
|
Sulfonylurea Compounds | 3 | 2024 | 220 | 0.360 |
Why?
|
Hypercholesterolemia | 2 | 2015 | 1145 | 0.350 |
Why?
|
Lipoprotein Lipase | 1 | 2011 | 133 | 0.350 |
Why?
|
Platelet Factor 4 | 3 | 2007 | 131 | 0.350 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2011 | 113 | 0.340 |
Why?
|
Aged | 52 | 2024 | 171343 | 0.340 |
Why?
|
Diabetes Complications | 2 | 2020 | 1319 | 0.340 |
Why?
|
Female | 84 | 2024 | 396520 | 0.340 |
Why?
|
Valine | 2 | 2008 | 410 | 0.330 |
Why?
|
Ambulatory Care | 2 | 2021 | 2779 | 0.320 |
Why?
|
Lipase | 1 | 2011 | 320 | 0.310 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 8045 | 0.290 |
Why?
|
Prospective Studies | 24 | 2023 | 54871 | 0.290 |
Why?
|
Disease Management | 1 | 2018 | 2533 | 0.280 |
Why?
|
Q Fever | 1 | 2007 | 38 | 0.280 |
Why?
|
Estrogen Replacement Therapy | 3 | 2011 | 1205 | 0.270 |
Why?
|
Male | 65 | 2024 | 364142 | 0.270 |
Why?
|
Interleukin-18 | 1 | 2008 | 251 | 0.270 |
Why?
|
Sex Characteristics | 1 | 2016 | 2645 | 0.260 |
Why?
|
Liver Diseases | 1 | 2014 | 1303 | 0.260 |
Why?
|
Extracellular Matrix Proteins | 1 | 2010 | 833 | 0.250 |
Why?
|
Follow-Up Studies | 19 | 2020 | 39309 | 0.250 |
Why?
|
Fibrinogen | 3 | 2016 | 893 | 0.250 |
Why?
|
Calcium-Binding Proteins | 1 | 2010 | 1078 | 0.250 |
Why?
|
Toll-Like Receptor 2 | 1 | 2007 | 347 | 0.250 |
Why?
|
Anticoagulants | 6 | 2023 | 4855 | 0.250 |
Why?
|
Tetrazoles | 2 | 2008 | 923 | 0.240 |
Why?
|
Intercellular Adhesion Molecule-1 | 4 | 2016 | 1131 | 0.240 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1104 | 0.240 |
Why?
|
Inflammation | 6 | 2020 | 10860 | 0.240 |
Why?
|
Diuretics | 1 | 2008 | 614 | 0.240 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2014 | 16044 | 0.240 |
Why?
|
Blood Proteins | 1 | 2010 | 1194 | 0.240 |
Why?
|
Cholesterol | 5 | 2024 | 2903 | 0.230 |
Why?
|
Heart | 1 | 2017 | 4425 | 0.230 |
Why?
|
Gangrene | 1 | 2024 | 92 | 0.230 |
Why?
|
Fibroblast Growth Factors | 1 | 2010 | 871 | 0.230 |
Why?
|
Inflammation Mediators | 3 | 2019 | 1889 | 0.230 |
Why?
|
Thromboembolism | 2 | 2010 | 1003 | 0.230 |
Why?
|
Toll-Like Receptor 4 | 1 | 2007 | 588 | 0.220 |
Why?
|
Cohort Studies | 19 | 2024 | 41710 | 0.220 |
Why?
|
Gout | 2 | 2022 | 622 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2021 | 10745 | 0.210 |
Why?
|
Risk | 7 | 2020 | 9602 | 0.210 |
Why?
|
Venous Thromboembolism | 2 | 2023 | 1882 | 0.210 |
Why?
|
Drug Therapy, Combination | 6 | 2017 | 6307 | 0.210 |
Why?
|
Antibodies | 3 | 2007 | 2421 | 0.200 |
Why?
|
Butyrates | 2 | 2024 | 164 | 0.200 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2021 | 2763 | 0.200 |
Why?
|
Proportional Hazards Models | 13 | 2021 | 12534 | 0.200 |
Why?
|
Glucose Metabolism Disorders | 1 | 2021 | 52 | 0.190 |
Why?
|
Antihypertensive Agents | 2 | 2008 | 2030 | 0.190 |
Why?
|
PPAR alpha | 1 | 2022 | 177 | 0.190 |
Why?
|
Angina, Unstable | 2 | 2016 | 893 | 0.190 |
Why?
|
Treatment Outcome | 16 | 2024 | 65273 | 0.190 |
Why?
|
Mass Screening | 1 | 2016 | 5454 | 0.180 |
Why?
|
Hypertension | 6 | 2016 | 8616 | 0.180 |
Why?
|
Natriuretic Peptides | 1 | 2021 | 156 | 0.180 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 104 | 0.170 |
Why?
|
Interleukin-6 | 5 | 2018 | 3227 | 0.170 |
Why?
|
Diabetic Foot | 1 | 2024 | 383 | 0.170 |
Why?
|
Life Style | 2 | 2024 | 3926 | 0.170 |
Why?
|
Brain Ischemia | 3 | 2011 | 3001 | 0.170 |
Why?
|
Azathioprine | 1 | 2021 | 354 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2018 | 10384 | 0.170 |
Why?
|
Secondary Prevention | 3 | 2021 | 1469 | 0.170 |
Why?
|
Hypertriglyceridemia | 1 | 2022 | 292 | 0.160 |
Why?
|
Lipoprotein(a) | 2 | 2014 | 489 | 0.160 |
Why?
|
Antioxidants | 2 | 2019 | 1671 | 0.160 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 349 | 0.160 |
Why?
|
Current Procedural Terminology | 1 | 2019 | 101 | 0.160 |
Why?
|
United States | 20 | 2024 | 72951 | 0.160 |
Why?
|
Blood Pressure | 3 | 2011 | 8533 | 0.160 |
Why?
|
Expert Testimony | 1 | 2020 | 266 | 0.150 |
Why?
|
Predictive Value of Tests | 7 | 2019 | 15416 | 0.150 |
Why?
|
Apolipoprotein A-I | 2 | 2011 | 305 | 0.150 |
Why?
|
Hemorrhage | 4 | 2023 | 3464 | 0.150 |
Why?
|
Diet | 1 | 2016 | 8088 | 0.150 |
Why?
|
Hypolipidemic Agents | 1 | 2022 | 609 | 0.150 |
Why?
|
Opportunistic Infections | 1 | 2021 | 376 | 0.150 |
Why?
|
Vaccination | 2 | 2021 | 3434 | 0.140 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4215 | 0.140 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4249 | 0.140 |
Why?
|
Thrombocytopenia | 4 | 2017 | 1172 | 0.140 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2306 | 0.130 |
Why?
|
Pyridones | 1 | 2021 | 818 | 0.130 |
Why?
|
Adult | 26 | 2024 | 223307 | 0.130 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 283 | 0.120 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2234 | 0.120 |
Why?
|
Coronary Artery Disease | 4 | 2018 | 6558 | 0.120 |
Why?
|
Clone Cells | 1 | 2019 | 1670 | 0.120 |
Why?
|
Incretins | 1 | 2016 | 100 | 0.120 |
Why?
|
Myocardial Revascularization | 2 | 2016 | 795 | 0.120 |
Why?
|
Cardiovascular System | 2 | 2020 | 839 | 0.120 |
Why?
|
Medicare | 6 | 2024 | 6820 | 0.120 |
Why?
|
Triglycerides | 2 | 2022 | 2441 | 0.120 |
Why?
|
Coronary Artery Bypass | 3 | 2021 | 2188 | 0.120 |
Why?
|
Algorithms | 4 | 2019 | 14072 | 0.120 |
Why?
|
Rheumatology | 1 | 2021 | 619 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1187 | 0.110 |
Why?
|
Placebos | 3 | 2020 | 1659 | 0.110 |
Why?
|
Infertility | 1 | 2021 | 655 | 0.110 |
Why?
|
Glucose | 5 | 2024 | 4340 | 0.110 |
Why?
|
International Classification of Diseases | 1 | 2019 | 935 | 0.110 |
Why?
|
Consensus | 2 | 2021 | 3208 | 0.110 |
Why?
|
Hospitalization | 7 | 2023 | 10823 | 0.110 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2014 | 378 | 0.100 |
Why?
|
Sodium | 3 | 2022 | 1594 | 0.100 |
Why?
|
Smoking | 5 | 2017 | 9077 | 0.100 |
Why?
|
Uric Acid | 1 | 2018 | 809 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2020 | 22248 | 0.100 |
Why?
|
Health Promotion | 1 | 2024 | 2209 | 0.100 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 350 | 0.100 |
Why?
|
Cardiac Surgical Procedures | 1 | 2007 | 3684 | 0.090 |
Why?
|
Advisory Committees | 1 | 2015 | 797 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2018 | 896 | 0.090 |
Why?
|
Propensity Score | 4 | 2021 | 1972 | 0.090 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15908 | 0.090 |
Why?
|
Pyrazoles | 1 | 2021 | 2030 | 0.090 |
Why?
|
Self Care | 1 | 2016 | 800 | 0.090 |
Why?
|
Health Literacy | 1 | 2016 | 466 | 0.090 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2014 | 347 | 0.090 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 1027 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1383 | 0.090 |
Why?
|
Genetic Markers | 2 | 2014 | 2603 | 0.090 |
Why?
|
Hyperlipidemias | 2 | 2022 | 771 | 0.080 |
Why?
|
Prognosis | 5 | 2019 | 29948 | 0.080 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 550 | 0.080 |
Why?
|
Vitamins | 2 | 2015 | 1631 | 0.080 |
Why?
|
Hematopoiesis | 1 | 2019 | 2060 | 0.080 |
Why?
|
Cardiology | 1 | 2020 | 1701 | 0.080 |
Why?
|
Leisure Activities | 1 | 2011 | 310 | 0.080 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2010 | 153 | 0.080 |
Why?
|
Endocarditis | 2 | 2010 | 352 | 0.080 |
Why?
|
Foot Diseases | 1 | 2010 | 148 | 0.080 |
Why?
|
Postoperative Period | 2 | 2018 | 1824 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2594 | 0.080 |
Why?
|
Comorbidity | 4 | 2018 | 10580 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 4 | 2014 | 18075 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2823 | 0.070 |
Why?
|
Primary Prevention | 1 | 2015 | 1188 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4142 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2390 | 0.070 |
Why?
|
Odds Ratio | 2 | 2021 | 9661 | 0.070 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1673 | 0.070 |
Why?
|
Plant Extracts | 1 | 2010 | 496 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1562 | 0.070 |
Why?
|
Embolism | 1 | 2009 | 401 | 0.070 |
Why?
|
Young Adult | 8 | 2021 | 59939 | 0.070 |
Why?
|
Cause of Death | 4 | 2021 | 3716 | 0.070 |
Why?
|
Caffeine | 1 | 2010 | 702 | 0.060 |
Why?
|
Adolescent | 8 | 2024 | 88904 | 0.060 |
Why?
|
Aging, Premature | 1 | 2005 | 44 | 0.060 |
Why?
|
Time Factors | 5 | 2019 | 40149 | 0.060 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 692 | 0.060 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 428 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6512 | 0.060 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2021 | 344 | 0.060 |
Why?
|
Lamin Type A | 1 | 2005 | 186 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1895 | 0.060 |
Why?
|
Body Mass Index | 2 | 2013 | 13050 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3804 | 0.050 |
Why?
|
Mortality | 3 | 2021 | 2910 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2022 | 81635 | 0.050 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3788 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8891 | 0.050 |
Why?
|
Heart Failure, Diastolic | 1 | 2023 | 77 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 88 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2010 | 6359 | 0.050 |
Why?
|
Body Weight | 1 | 2013 | 4626 | 0.050 |
Why?
|
Neutropenia | 2 | 2017 | 894 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2010 | 5444 | 0.050 |
Why?
|
Age Factors | 3 | 2016 | 18397 | 0.050 |
Why?
|
Disease Progression | 1 | 2019 | 13640 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 70 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 4056 | 0.050 |
Why?
|
Immunity | 1 | 2007 | 1002 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10619 | 0.050 |
Why?
|
Apolipoprotein C-III | 1 | 2022 | 209 | 0.050 |
Why?
|
Matched-Pair Analysis | 1 | 2021 | 285 | 0.050 |
Why?
|
Committee Membership | 1 | 2020 | 18 | 0.040 |
Why?
|
Electrocardiography | 2 | 2011 | 6408 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4045 | 0.040 |
Why?
|
Multi-Institutional Systems | 1 | 2019 | 43 | 0.040 |
Why?
|
Insulin | 2 | 2016 | 6608 | 0.040 |
Why?
|
Pleurisy | 1 | 2019 | 54 | 0.040 |
Why?
|
Alleles | 1 | 2011 | 6895 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 13476 | 0.040 |
Why?
|
Self Report | 1 | 2011 | 3771 | 0.040 |
Why?
|
Databases, Factual | 3 | 2020 | 8066 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14762 | 0.040 |
Why?
|
Toes | 2 | 2010 | 209 | 0.040 |
Why?
|
Europe | 2 | 2016 | 3430 | 0.040 |
Why?
|
Clinical Coding | 1 | 2019 | 187 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 198 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2019 | 239 | 0.040 |
Why?
|
Preoperative Care | 1 | 2007 | 2253 | 0.040 |
Why?
|
Osteonecrosis | 1 | 2019 | 230 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2020 | 374 | 0.040 |
Why?
|
Limit of Detection | 1 | 2018 | 271 | 0.040 |
Why?
|
Hospital Information Systems | 1 | 2019 | 395 | 0.040 |
Why?
|
Hospital Mortality | 2 | 2021 | 5343 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 6207 | 0.030 |
Why?
|
Liver Neoplasms | 2 | 2010 | 4353 | 0.030 |
Why?
|
Logistic Models | 3 | 2021 | 13278 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 684 | 0.030 |
Why?
|
Delphi Technique | 1 | 2021 | 892 | 0.030 |
Why?
|
Depression | 1 | 2016 | 8228 | 0.030 |
Why?
|
Pleural Effusion | 1 | 2019 | 344 | 0.030 |
Why?
|
Lupus Nephritis | 1 | 2019 | 324 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14652 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23619 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 592 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2659 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2010 | 1838 | 0.030 |
Why?
|
Critical Pathways | 1 | 2018 | 475 | 0.030 |
Why?
|
Indians, North American | 1 | 2018 | 354 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2869 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1010 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1120 | 0.030 |
Why?
|
Athletes | 1 | 2021 | 1161 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2018 | 2921 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2846 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13485 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1263 | 0.030 |
Why?
|
Outpatients | 1 | 2019 | 1596 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1188 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4853 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4344 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2727 | 0.020 |
Why?
|
United Arab Emirates | 1 | 2009 | 42 | 0.020 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 59 | 0.020 |
Why?
|
Japan | 1 | 2014 | 1417 | 0.020 |
Why?
|
Cryoglobulinemia | 1 | 2009 | 84 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1663 | 0.020 |
Why?
|
Educational Status | 1 | 2016 | 2510 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10100 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2693 | 0.020 |
Why?
|
Poverty | 1 | 2020 | 2714 | 0.020 |
Why?
|
Infarction | 1 | 2010 | 247 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2750 | 0.020 |
Why?
|
Hemianopsia | 1 | 2009 | 121 | 0.020 |
Why?
|
Antiphospholipid Syndrome | 1 | 2009 | 166 | 0.020 |
Why?
|
Regression Analysis | 1 | 2017 | 6329 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2839 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 347 | 0.020 |
Why?
|
Fingers | 1 | 2010 | 508 | 0.020 |
Why?
|
Neoplasms | 1 | 2015 | 22350 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2009 | 1606 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12825 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2014 | 4619 | 0.020 |
Why?
|
Beverages | 1 | 2010 | 819 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3432 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2430 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12985 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6850 | 0.010 |
Why?
|
Glucuronidase | 1 | 2005 | 205 | 0.010 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1721 | 0.010 |
Why?
|
Echocardiography, Transesophageal | 1 | 2010 | 1093 | 0.010 |
Why?
|
Platelet Count | 1 | 2006 | 784 | 0.010 |
Why?
|
Reference Values | 1 | 2011 | 4913 | 0.010 |
Why?
|
Sepsis | 1 | 2017 | 2604 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1326 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8728 | 0.010 |
Why?
|
Vision Disorders | 1 | 2010 | 1090 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 20144 | 0.010 |
Why?
|
Ischemia | 1 | 2010 | 1905 | 0.010 |
Why?
|
Data Collection | 1 | 2010 | 3321 | 0.010 |
Why?
|
Stroke Volume | 1 | 2014 | 5618 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2016 | 59550 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2011 | 2085 | 0.010 |
Why?
|
Syndrome | 1 | 2005 | 3271 | 0.010 |
Why?
|
Weight Loss | 1 | 2010 | 2712 | 0.010 |
Why?
|
Health Personnel | 1 | 2011 | 3384 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 26310 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12150 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7571 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7475 | 0.010 |
Why?
|
Genotype | 1 | 2005 | 13036 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2005 | 7868 | 0.000 |
Why?
|
Obesity | 1 | 2007 | 13090 | 0.000 |
Why?
|
Brain | 1 | 2010 | 27159 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 36567 | 0.000 |
Why?
|